Wound Care Collaborative Community: Post-Summit Interview With Katie Mowry
© 2024 HMP Global. All Rights Reserved. Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Wound Care Learning Network or HMP Global, their employees, and affiliates.
HMP Global’s Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) partnered with the Wound Care Collaborative Community (WCCC) to host the inaugural Driving Innovation in Wound Care Summit, addressing public policy challenges related to assuring patients receive access to wound-healing therapies.
Transcript:
Katie Mowry, PhD; VP, Research and Development, Organogenesis
I'm Katie Mowry. I'm the Vice President of Research and Development for Organogenesis. First of all, Organogenesis is so excited to be partnering with WCCC to support this important work.
We're just so pleased to have this collaborative community coming together. it's one of the only times I've seen collaboration from all the important participants, including regulatory, industry, providers, as well as academia. So just wanted to point that out first.
It's been a great environment and a great experience. The meeting was just so exciting. From an industry perspective, what we're excited about and what we should do to help move the work forward is embrace it as it comes forward.
We talked a lot about reporting standards, about standard of care and how to implement those things, and what I think we can do from our perspective is hold ourselves accountable when those standards come out and make sure we're using them—make sure we're reporting that way, publishing that way—because we've got to make these things stick. We can do all the work in the world, but if we don't do them in a way that they stick and they're utilized across the board, they'll just fade out too. From my perspective, I think that's how we can hold ourselves accountable. There were a lot of interesting things discussed.
I won't try to hit them all, but one of the things that I thought was super interesting was the work being done around real-world evidence and how to define what that looks like and get buy-in from all the parties. The real-world evidence argument is a way to look at how these products might perform in real use. In our clinical studies—it was pointed out during the meeting and it's been pointed out by others—and in a lot of the randomized controlled trials, you have to include or exclude a large percentage of the population that receives these products. By looking at real-world evidence along with RCTs, you're able to see the majority of the patients that are actually getting these types of products.
I was excited about the real-world evidence perspective and how we might be able to utilize that to support products and innovations and move things forward faster. RCTs are great, but they take a really long time. If we can figure out a way to utilize and move forward the use of real-world evidence in a way that is able to show us whether it's effective, whether it's safe, and keep those same standards but doing a more innovative and quick way, it would be great.
I'm really excited about that one. Outside of the real-world evidence project, the other one I thought was cool was the natural history project in the same way that you're getting a look at what's really happening. You're getting a look at the impact of comorbidities and mixed etiology wounds and how that might be impacting wound healing, and you're also seeing how people are using what's out there today. I think when you pair that with the standard of care work stream of here's what's happening today and then defining as a big collaborative group what we think best practices are, eventually you can marry those together and really improve patient care and hopefully get alignment from the entire community behind them.
I'm just looking forward to the meeting continuing next year and hopefully, we can continue to advance these important work streams.
